Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Lumora

Claya
Graded #268

Lower grade

vs+3.299999999999997
Lumora
Graded #205

Higher grade

The verdict

Lumora takes it — 66.1/100 to 62.8/100.

Lumora grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lumora (Blue Skies MD LLC dba Lumora MD) is a physician-founded telehealth platform offering compounded semaglutide and tirzepatide in injectable and sublingual forms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueClaya +6
42
36
Dose & formulationEven
75
75
Clinical oversightLumora +5
82
87
Labs & monitoringLumora +23
53
76
FulfillmentLumora +7
67
74
Contract termsClaya +6
61
55
Claya · left barLumora · right bar

The numbers

MetricClayaLumora
WeighScore62.8/10066.1/100
GradeCC
Scorecard rank#268#205
Semaglutide$299/mo (compounded)$199/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$299/mo (compounded)$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Lumora

Graded #205 · C

Strengths

  • Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
  • Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
  • LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
  • Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
  • Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141

Where it loses points

  • Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
  • Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
  • Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
  • No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
  • Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard